|Bid||28.37 x 800|
|Ask||28.39 x 800|
|Day's range||27.58 - 28.59|
|52-week range||18.21 - 58.00|
|Beta (5Y monthly)||-0.41|
|PE ratio (TTM)||3.22|
|Earnings date||02 Nov 2022 - 07 Nov 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||54.83|
Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of -241.18% and 129.79%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Avidity Biosciences, Inc. (RNA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
It's really exciting to see triple-digit revenue growth. ShockWave Medical (NASDAQ: SWAV) and BioCryst Pharmaceuticals (NASDAQ: BCRX) are blowing the roof off right now, with 194% and 162% sales increases, respectively.